论文部分内容阅读
目的探讨右美托咪定对子宫颈癌手术患者围术期免疫状态的影响。方法选择襄阳市襄州区中医院2013年1月—2015年1月收治的子宫颈癌手术患者50例,随机分为观察组和对照组,各25例。对照组泵入0.9%氯化钠溶液,观察组采用右美托咪定进行静脉泵注,比较两组患者的免疫状态指标检测结果。结果 CD_3~+、CD_4~+、CD_8~+、CD_4~+/CD_8~+、CD_(16)~+/CD_(56)~+时间和方法有交互作用,差异有统计学意义(P<0.05);时间间比较,差异有统计学意义(P<0.05);组间比较,差异有统计学意义(P<0.05)。两组患者CD_3~+、CD_4~+、CD_8~+、CD_4~+/CD_8~+、CD_(16)~+/CD_(56)~+在T1、T2时间点比较,差异有统计学意义(P<0.05);两组患者CD_3~+、CD_4~+、CD_8~+、CD_4~+/CD_8~+、CD_(16)~+/CD_(56)~+在T3时间点比较,差异无统计学意义(P>0.05)。两组患者T0时间点CD_3~+、CD_4~+、CD_8~+、CD_4~+/CD_8~+、CD_(16)~+/CD_(56)~+与T1、T2时间点比较,差异有统计学意义(P<0.05)。两组患者术后均未出现尿潴留、低血压、呼吸抑制等并发症。结论右美托咪定对子宫颈癌手术患者围术期免疫状态具有明显的改善作用,能够有效减少免疫细胞的减少量。
Objective To investigate the effect of dexmedetomidine on perioperative immune status in patients with cervical cancer. Methods Fifty cases of cervical cancer patients admitted from January 2013 to January 2015 in Xiangzhou District Chinese Medicine Hospital of Xiangyang were randomly divided into observation group and control group with 25 cases each. The control group was pumped 0.9% sodium chloride solution, the observation group was treated with intravenous infusion of dexmedetomidine, and the results of immune status index test were compared between the two groups. Results There was interaction between CD_3 ~ +, CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ + and CD16 ~ + / CD56 ~ + time and the method had statistical significance (P <0.05 (P <0.05). There was a significant difference between the two groups (P <0.05). The differences of CD_3 ~ +, CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ + and CD16 ~ + / CD56 ~ + in both groups at T1 and T2 were statistically significant P <0.05). There was no significant difference in the time points of T3, CD3, CD4, CD8, CD4 + CD8 + CD16 + between the two groups Significance (P> 0.05). There was statistical difference between the two groups at the T0 time point, CD_3 ~ +, CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ +, CD16 ~ + / CD_ (56) ~ + Significance (P <0.05). No postoperative urinary retention, hypotension, respiratory depression and other complications occurred in both groups. Conclusion Dexmedetomidine can significantly improve perioperative immune status of patients with cervical cancer and can effectively reduce the reduction of immune cells.